2022-04-25-港交所-正大企业国际_二零二一年年报_146页_1mb

Summary of Chia Tai Enterprises International Limited's 2021 Annual Report

1. Performance Overview

   • In 2021, the COVID-19 pandemic and global economic uncertainties impacted the company's operations.
   • Revenue increased by 52.2% to USD 142.4 million, with gross profit margin declining from 26.6% to 24.4%.
   • The company successfully shifted its biochemical business focus to farms to adapt to market demands, achieving solid growth.

2. Biochemical Business

   • Largely driven by the sale of chlortetracycline, revenue rose significantly despite challenges like raw material price hikes.
   • Market shifts, such as moving sales to farms, helped sustain performance.

3. Industrial Business

   • Fixed asset investments increased, but intense competition in machinery trading affected margins.
   • Zhanjiang Deni's automotive parts business showed relatively stable performance.

4. Financial Highlights

   • Profit attributable to shareholders was USD 19.56 million, up from USD 16.26 million in 2020.
   • Basic earnings per share reached 7.72 US cents, reflecting improved operational efficiency.
   • No dividends were declared for the year.

5. Key Risks

   • Susceptible to product demand fluctuations, raw material price volatility, and intense market competition.
   • Expansion of fixed assets added pressure on financial resources, but strategic cost management mitigated risks.

6. Corporate Governance

   • The Board maintained strong oversight, with mechanisms to ensure compliance and shareholder interests.
   • Independent directors played a pivotal role in corporate governance and risk management.

Overall, 2021 was challenging, but the company demonstrated resilience through adaptive strategies, achieving revenue growth and solid financial performance in key business segments.